Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 118
Study Ref Population Intervention Outcomes Results Comments Study
type
EL
and HBIG within 24
hours of birth. Further
group
HBV vaccine
doses at 4 and 8 weeks
respectively (n = 27)
RR 2.6 (95%CI 0.29, 23.4)
Xu et al., 4 208 pregnant mothers Group 1: BIVS vaccine HBsAg carrier state in HBV carrier rate:
BIVS = Beijing Institute of RCT 1b
1985 [392] with HBsAg from for hepatitis B virus infants at 6 months (n Group 1: 12/56 Vaccine and Serum vaccine
antenatal clinics in within 24 hours of = 5, 5, 4, and 1 lost to (21.4%)
Shanghai from 1982 to birth and at 1 and 6 follow-up, for each
Group 2: 3/55 (5.4%) NIAID = National Institute of
1984
months of age (n = 60) group respectively)
Group 3: 2/27 (7.4%) Allergy and Infectious disease
Group 4: 24/55
(43.6%)
vaccine
Group 2: NIAID
vaccine for hepatitis B
virus within 24 hours
of birth and at 1 and 6
months of age (n = 60)
Group 3: BIVS vaccine
for hepatitis B virus
plus HBIG within 24
hours of birth and
further vaccine only at
1 and 6 months of age
(n = 60)
Group 4: placebo
within 24 hours of
birth and at 1 and
6 months of age (n =
28)
Group 4 vs. group 1: RR
0.49 (95% CI 0.27 to 0.88)
Group 4 vs. group 2: RR
0.13 (95% CI 0.40 to 0.39)
Group 4 vs. group 3: RR
0.17 (95% CI 0.04 to 0.67)